MTOR and Kaposi's sarcoma: The PI3K/Akt/mTOR pathway has proven to be vital for KS and PEL, and several inhibitors have proven to be efficacious in pre-clinical studies (Sin et al., 2007; Bhatt et al., 2010; Roy et al., 2013).